X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cancer (3) 3
care and treatment (3) 3
humans (3) 3
immunotherapy (3) 3
index medicus (3) 3
metastasis (3) 3
oncology (3) 3
tumors (3) 3
abridged index medicus (2) 2
advanced melanoma (2) 2
aged (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents - administration & dosage (2) 2
b7-h1 antigen - immunology (2) 2
bladder cancer (2) 2
bladder-cancer (2) 2
carcinoma (2) 2
cell lung-cancer (2) 2
chemotherapy (2) 2
clinical activity (2) 2
clinical trials (2) 2
ctla-4 blockade (2) 2
female (2) 2
immunology (2) 2
infusions, intravenous (2) 2
internal medicine (2) 2
ligands (2) 2
male (2) 2
medical colleges (2) 2
medicine, general & internal (2) 2
middle aged (2) 2
mutation (2) 2
nivolumab (2) 2
patients (2) 2
pd-1 (2) 2
pd-1 blockade (2) 2
pd-l1 (2) 2
response evaluation criteria in solid tumors (2) 2
untreated melanoma (2) 2
urologic neoplasms - drug therapy (2) 2
adult (1) 1
analysis (1) 1
angiomyolipoma (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
b7-h1 antigen - antagonists & inhibitors (1) 1
b7-h1 antigen - blood (1) 1
biomarkers (1) 1
biomarkers, tumor - blood (1) 1
cancer therapies (1) 1
carboplatin - administration & dosage (1) 1
carcinoma, transitional cell - blood (1) 1
carcinoma, transitional cell - drug therapy (1) 1
carcinoma, transitional cell - secondary (1) 1
case report (1) 1
cd8 t-cells (1) 1
cell carcinoma (1) 1
checkpoint inhibitors (1) 1
cisplatin (1) 1
cisplatin - administration & dosage (1) 1
contraindications (1) 1
disease progression (1) 1
doxorubicin (1) 1
drug administration schedule (1) 1
everolimus (1) 1
fda approval (1) 1
gemcitabine (1) 1
gene expression (1) 1
genomes (1) 1
immune-related response (1) 1
immunoglobulins, intravenous - administration & dosage (1) 1
immunohistochemistry (1) 1
immunotherapy - methods (1) 1
inflamed tumor microenvironment (1) 1
kaplan-meier estimate (1) 1
long-term safety (1) 1
long-term-survival (1) 1
lymphatic metastasis (1) 1
mammalian target (1) 1
medical prognosis (1) 1
melanoma (1) 1
methotrexate (1) 1
microbiome (1) 1
monoclonal antibodies (1) 1
mtor (1) 1
mutation - genetics (1) 1
neoplasm metastasis (1) 1
neoplasms - drug therapy (1) 1
neoplasms - immunology (1) 1
neoplasms. tumors. oncology. including cancer and carcinogens (1) 1
open-label (1) 1
pecoma (1) 1
plus ipilimumab ipi (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 67 - 76
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 10/2018, Volume 6, Issue 1, pp. 97 - 7
Background: Malignant angiomyolipoma is an uncommon tumor of the class of perivasciular epithelioid cell neoplasms (PEComas). These tumors are... 
MAMMALIAN TARGET | PEComa | PD-1 BLOCKADE | Tuberous sclerosis | TSC2 | IMMUNOLOGY | CANCER | TUMORS | TUBEROUS SCLEROSIS COMPLEX | RENAL ANGIOMYOLIPOMA | ONCOLOGY | ADVANCED MELANOMA | Immunotherapy | Nivolumab | PD-L1 | mTOR | Angiomyolipoma | PD-1 | Everolimus | SIROLIMUS | Immunohistochemistry | Practice guidelines (Medicine) | Care and treatment | T cells | Cancer | Melanoma | Metastasis | FDA approval | Mutation | Patients | Tumors
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 05/2017, Volume 66, Issue 5, pp. 551 - 564
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.